Human heterologous liver cells    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
251Urea cycle disorder3

251. Urea cycle disorder    [ 42 clinical trials,   45 drugs,   (DrugBank: 10 drugs),   4 drug target genes,   29 drug target pathways]
Searched query = "Urea cycle disorder", "N-acetylglutamate synthase deficiency", "NAGS deficiency", "Carbamoyl phosphate synthetase I deficiency", "CPS1 deficiency", "Ornithine transcarbamylase deficiency", "OTC deficiency", "Classic citrullinemia", "Citrullinemia type I", "Argininosuccinic aciduria", "Argininemia", "Hiperornitinemia-hiperamonemia-homocitrulinuria syndrome", "HHH syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 42 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00718627
(ClinicalTrials.gov)
July 200816/7/2008Human Heterologous Liver Cells for Infusion in Children With Urea Cycle DisordersOpen, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children With Urea Cycle Disorders (UCDs)Urea Cycle Disorders;Carbamoylphosphate Synthetase I Deficiency;Ornithine Transcarbamylase Deficiency;CitrullinemiaBiological: Human Heterologous Liver CellsCytonet GmbH & Co. KGNULLCompletedN/A5 YearsBoth12Phase 2Germany
2EUCTR2006-000136-27-DE
(EUCTR)
17/03/200804/09/2007Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children with Urea Cycle Disorders (UCDs)Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children with Urea Cycle Disorders (UCDs) Neonates and Infants up to 3 months including with prenatally or postnatally confirmed urea cycle disorder with below listed deficiency and children aged > 3 months up to 5 years including with confirmed urea cycle disorder and unstable metabolism with deficiency of either: - Carbamyl-phosphate Synthetase I Deficiency (CPS1D) - Ornithine Transcarbamylase Deficiency (OTCD) - Argininosuccinate Synthetase Deficiency (ASSD/Citrullinaemia)can be included.
MedDRA version: 18.1;Level: PT;Classification code 10052450;Term: Ornithine transcarbamoylase deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 18.1;Classification code 10058298;Term: Argininosuccinate synthetase deficiency;Classification code 10058297;Term: Carbamoyl phosphate synthetase deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: Human heterologous liver cells (for infusion)
Product Code: HHLivC
Cytonet GmbH & Co KGNULLNot RecruitingFemale: yes
Male: yes
Germany
3EUCTR2015-000988-14-Outside-EU/EEA
(EUCTR)
12/10/2016Human Heterologous Liver Cells for Infusion in Children With Urea Cycle DisordersTitle: Open, Prospective, Historic-Controlled, Multicenter Study toEvaluate the Safety and Efficacy of Infusion of Liver Cell Suspension(HHLivC) in Children with Urea Cycle Disorders Neonatal-onset type of the following urea cycle disorders(UCD):ornithine transcarbamylase deficiency (OTCD),carbamoylphosphate synthetase I deficiency (CPS1D), orargininosuccinate synthetase deficiency (ASSD orcitrullinemia);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Product Name: Heparesc
Product Code: HHLivC
INN or Proposed INN: not available
Other descriptive name: ALLOGENIC HUMAN HETEROLOGOUS LIVER CELLS
PROMETHERA Biosciences S.A./N.V.NULLNAFemale: yes
Male: yes
21Phase 2United States;Canada